Myriad Genetics, Inc. (Nasdaq: MYGN)
A class action has been filed in the United States District Court for the District of Utah on behalf of purchasers of Myriad Genetics, Inc. (Nasdaq: MYGN) securities during the period between September 2, 2016 and August 13, 2019, (the “Class Period”).
The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that the FDA requested changes to GeneSight® and the Company had been in ongoing discussions with the FDA about the request. Defendants revealed that the FDA had specifically questioned the company as to whether the validity of GeneSight's purported benefits had been established.
This news drove the price of Myriad shares down $19.05, or down almost 43%, to close at $25.50 on August 14, 2019, erasing $1.4 billion in market capitalization.
If you are a current shareholder and/or purchased stock during the period between September 2, 2016 and August 13, 2019, and would like to discuss your options of exercising your rights as a shareholder, please contact us.
Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.